In a pediatric refractory AML patient, the concurrent blockade of CTLA-4, PD-L1, and HMA initially improved symptom control without adverse events, but ultimately was not able to stop the lethal progression. The gene discussed is CTLA4; the disease is acute myeloid leukemia.